Cinarizine - instructions for use, dose, side effects, contraindications

Excipients: lactose (milk sugar), potato starch, calcium stearate, povidone (low molecular weight medical polyvinylpyrrolidone 12600 ± 2700), silicon dioxide colloid (aerosil), vaseline oil.

Description:Tablets white or white with a creamy shade of color, flat-cylindrical with a bevel.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

Selective blocker slow calcium channels, reduces the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, lowers the tone of the smooth muscle arterioles. Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood. Increases muscle resistance to hypoxia.

Pharmacokinetics:

Absorbed in the stomach and intestines. The maximum concentration in the blood plasma after ingestion is 1-3 hours. The connection with plasma proteins is 91%. It is completely metabolized in the liver (via glucuronation). The half-life is 4 hours. It is excreted in the form of metabolites: 1/3 - kidneys and 2/3 - with fecal masses.

Indications:

symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration of attention);
vestibular disorders (including Meniere's disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin);
prevention of kinetosis ("road sickness" - sea and air sickness);
migraine (prevention of seizures);
violations of peripheral circulation: Raynaud's disease, "intermittent" lameness, acrocyanosis, trophic disorders (including trophic and varicose ulcers).

Contraindications:

Hypersensitivity, pregnancy, lactation, children under 5 years.

Carefully:

Parkinson's disease.

Dosing and Administration:

Inside, after eating.

With insufficiency of cerebral circulation: 25 mg three times a day.

If peripheral circulation is disturbed, 50-75 mg three times a day. With vestibular disorders - 25 mg three times a day.

The maximum recommended dose should not exceed 225 mg (9 tablets) per day. The course of treatment is from several weeks to several months.

In kinetosis ("road" disease): adults - 25 mg for half an hour before the road (if necessary, repeated intake of 25 mg after 6 hours), for children from 5 years - ½ the dose recommended by an adult.

With high sensitivity to the drug, treatment starts with ½ dose, increasing it gradually.

Side effects:

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (tremor of limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: sweating, development of lupus-like syndrome, red flat lichen (extremely rare), skin rash.

Other: allergic reactions, weight gain.

Overdose:

Symptoms: increased severity of side effects, lower blood pressure, vomiting, coma.

Treatment: There is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.

Interaction:

Strengthens the depressing effect on the central nervous system of alcohol, sedatives, tricyclic antidepressants. In connection with the presence of antihistamine effect, cinnarizine can affect the results of anti-doping control athletes (false positive result),and also can neutralize positive reactions during skin diagnostic tests (for 4 days before the study treatment should be canceled).

Special instructions:

Patients with Parkinson's disease, the drug is prescribed only in cases when the benefits of cinnarizine treatment outweigh the possible worsening of the course of the underlying disease.

In connection with the antihistamine effect, the appointment of cinnarizine should be discontinued 4 days before the allergic skin test. Cinnarizine can affect the result in the anti-doping control of athletes (false positive result).

Patients with intolerance to lactose, it should be noted that the drug contains it as an auxiliary.

With prolonged use, it is recommended that a control laboratory examination of the liver, kidneys, and peripheral blood is recommended.

Effect on the ability to drive transp. cf. and fur:

It is possible to develop drowsiness, especially at the beginning of treatment, therefore, care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

Form release / dosage:

Tablets 25 mg.

Packaging:

10 pieces per contour cell pack.

For 1, 2, 3 or 5 contour squares, together with the instruction for use, is placed in a cardboard package.

For 50 or 100 tablets in cans of orange glass or in cans of polymeric. Each bank along with the instruction for use is placed in a cardboard pack.

Storage conditions:

In dry, protected from light, out of reach of children at a temperature of no higher than 25 ° C.

Shelf life:

2 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N001053 / 01

Date of registration:27.03.2007

The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia

Manufacturer: & nbsp

DALHIMFARM, OJSC Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)